March 30, 2020

**BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531
Scrip code: STAR

Dear Madam/ Sir,

**Subject: Press Release**

Please find attached Press Release issued by the Company titled:

“Strides announces successful completion of US FDA inspection conducted in January 2020 at flagship facility in Bangalore”

Thanking you,

Yours faithfully,

For **Strides Pharma Science Limited**

Manjula Ramamurthy
Company Secretary

Encl. As above
Strides announces successful completion of US FDA inspection conducted in January 2020 at flagship facility in Bangalore

Inspection conducted in January 2020 was for specific Extended Release applications

Bangalore, March 30, 2020 - Strides Pharma Science Limited (Strides) today announced that it has received the Establishment Inspection Report (EIR) for the inspection conducted by the USFDA in January 2020 at Company’s flagship facility KRS Gardens, Bangalore. The inspection was related to specific Extended Release applications made from the site. Receipt of EIR confirms the successful closure of the inspections.

The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility is also capable of manufacturing complex formulations of Extended Release tablets which is one of the focus area’s for the company. Strides has a large Extended Release portfolio for the US and other regulated markets with a capability to manufacture these products at multiple sites.

Strides had recently also received EIR for Bangalore facility from USFDA for the inspection conducted in March 2020 and the same was intimated to Stock Exchanges on March 26, 2020.

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. R Ananthnarayanan</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>CEO &amp; Managing Director</td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td>+91 80 6784 0335</td>
<td><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
<tr>
<td>Badree Komandur</td>
<td>K Priya: +91 95354 25418</td>
</tr>
<tr>
<td>Executive Director - Finance</td>
<td><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td></td>
</tr>
</tbody>
</table>
Investor Relations

Kannan. N: +91 98450 54745
Vikesh Kumar: +91 80 6784 0827
Sandeep Baid: +91 80 6784 0791
Email: Sandeep.baid@strides.com

Strides Pharma Science Limited
(Formerly Strides Shasun Limited)
CIN: L24230MH1990PLC057062

Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560 076